文献速递肝肾功能剂量调整特殊人群用药药物相互作用

替格列汀独特的药理学与药代动力学特征:对临床实践的启示

The Unique Pharmacological and Pharmacokinetic Profile of Teneligliptin: Implications for Clinical Practice.
PubMed 文献 · Drugs · 2019-01-01

替格列汀是一种强效、选择性、长效的DPP-4抑制剂,半衰期约24小时,经CYP3A4和FMO3代谢或经肾以原形排泄。其多途径消除特性使其在肝或肾功能不全患者中无需调整剂量,且被认为药物相互作用风险低。临床研究和上市后监测显示,替格列汀单药或联合降糖药治疗T2DM有效且耐受良好,包括老年和肾功能不全患者;此外,它具有抗氧化和内皮保护作用。

要点

  • 替格列汀半衰期约24小时,经CYP3A4和FMO3代谢及肾原形排泄,多途径消除。
  • 肝或肾功能不全患者无需调整剂量,药物相互作用风险低。
  • 单药或联合降糖药对T2DM有效且耐受良好,包括老年和肾功能不全患者。

核心结论

  • 替格列汀因独特药理学和药代动力学特征,是包括老年和肾功能不全患者在内的广泛T2DM患者的潜在治疗选择。
  • 替格列汀具有抗氧化特性和内皮保护作用,可能提供额外获益。

研究设计与样本

  • 综述性文章,总结替格列汀的药理学、药代动力学特征及临床研究、上市后监测数据。

主要发现

  • 替格列汀半衰期约24小时,经CYP3A4和FMO3代谢或经肾以原形排泄。
  • 临床研究和上市后监测显示,替格列汀单药和/或联合降糖药治疗T2DM有效且耐受良好,包括老年和肾功能不全患者。
  • 替格列汀具有抗氧化特性,诱导抗氧化级联反应,并具有·OH清除特性;在多项非临床和临床研究中显示内皮保护作用。

关键数值与推荐

  • 肝或肾功能不全患者无需剂量调整。
  • 药物相互作用风险低。

临床怎么用

  • 替格列汀可用于广泛T2DM患者,包括老年和肾功能不全患者,无需根据肝肾功能调整剂量。
  • 替格列汀与坎格列净的固定剂量复方片已在日本获批,可能提供额外处方和依从性获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Teneligliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that was approved for the treatment of type 2 diabetes mellitus (T2DM) in Japan and Korea and is being researched in several countries. Teneligliptin is a potent, selective, and long-lasting DPP-4 inhibitor with a t½ of approximately 24 h and unique pharmacokinetic properties: it is metabolized by cytochrome P450 (CYP) 3A4 and flavin-containing monooxygenase 3 (FMO3), or excreted from the kidney in an unchanged form. Because of its multiple elimination pathways, dose adjustment is not needed in patients with hepatic or renal impairment, and it is considered to have a low potential for drug-drug interactions. Clinical studies and postmarketing surveillance show that teneligliptin, administered as monotherapy and/or in combination with antihyperglycemic agents, is effective and well tolerated in T2DM patients, including in elderly patients and those with renal impairment. Furthermore, teneligliptin has antioxidative properties, which induce the antioxidant cascade, as well as ·OH scavenging properties. In addition, it has shown endothelial protective effects in several non-clinical and clinical studies. From its unique profile and clinical data, teneligliptin represents a potential therapeutic option in a wide variety of patients, including elderly diabetic patients and those with renal impairment. The fixed-dose combination (FDC) tablet of teneligliptin and canagliflozin has been approved in Japan; this is the first FDC tablet of a DPP-4 inhibitor and sodium glucose co-transporter 2 inhibitor in Japan, and the third globally. The FDC tablet may also provide additional prescribing and adherence benefits.

来源:Drugs,查看原文。版权归原作者所有。

引用

  1. Ceriello A, De Nigris V, Iijima H, et al. The Unique Pharmacological and Pharmacokinetic Profile of Teneligliptin: Implications for Clinical Practice. Drugs. 2019. PMID: 30982160. doi:10.1007/s40265-019-01086-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。